China's Top Bank Reports 6% Profit Rise
By wchung | 22 Jun, 2026
Industrial & Commercial Bank of China Ltd., the country’s biggest commercial lender by assets, said Monday its quarterly profit rose 6 percent from a year earlier despite a double-digit fall in interest income.
Profit for the three months ending March 31 was 35.1 billion yuan ($5.1 billion), or 0.11 yuan per share, the Beijing-based lender said.
Net interest income fell 12.9 percent from a year earlier to 57.8 billion yuan ($8.4 billion) as the spread between benchmark rates and financial market rates narrowed, the bank said. Other lenders have suffered a similar squeeze after repeated rate cuts by China’s central bank to boost economic growth amid the global financial crisis.
ICBC’s fee and commission income for the quarter rose 9.7 percent to 13.5 billion yuan ($2 billion), the bank said.
China’s mostly state-owned banking industry is isolated from global financial flows and has avoided the mortgage-related turmoil that is battering Western institutions.
ICBC said its total assets rose 12.5 percent over the course of the quarter to 11 trillion yuan ($1.6 trillion).
The bank reported a 35.2 percent increase in annual profit in 2008 but warned of “severe challenges” this year.
China’s second-largest commercial lender, China Construction Bank Ltd., reported earlier its first quarter profit fell 18 percent due to smaller net interest income.
4/27/2009 5:59 AM BEIJING (AP)
Recent Articles
- Become an AI Bonus Baby—or Just Get Paid Like One
- Ferrari Denies Requiring Luce EV Purchase to Access to Limited Edition Models
- SpaceX Turns to Bond Sale to Fatten $100.8 Billion Cash Stash
- Google DeepMind Signs AI Research Deal with Film Studio A24
- China's 618 Shopping Festival Sees Flat E-Commerce Sales from Cautious Shoppers
- Amazon Prime Day to Gauge US Consumer Strain as Focus Shifts to Basics
- China Closing in but US Still Leads in Biotech Innovation
- EV Surge Likely to Cut Oil Demand by Late 2027
- Kunal Shah tapped to Lead Meta's WhatsApp
- AbbVie Bets $10.9 Billion on Apogee in Next-Generation Immunology Growth Push
